Jabbour, Elias http://orcid.org/0000-0003-4465-6119
Apperley, Jane http://orcid.org/0000-0002-1710-1794
Cortes, Jorge http://orcid.org/0000-0002-8636-1071
Rea, Delphine http://orcid.org/0000-0001-5379-7461
Deininger, Michael http://orcid.org/0000-0002-2987-1331
Abruzzese, Elisabetta http://orcid.org/0000-0001-5228-6491
Chuah, Charles
DeAngelo, Daniel J. http://orcid.org/0000-0001-7865-2306
Hochhaus, Andreas http://orcid.org/0000-0003-0626-0834
Lipton, Jeffrey H.
Mauro, Michael http://orcid.org/0000-0002-2251-4032
Nicolini, Franck
Pinilla-Ibarz, Javier
Rosti, Gianantonio
Rousselot, Philippe
Shah, Neil P.
Talpaz, Moshe
Vorog, Alexander
Ren, Xiaowei
Kantarjian, Hagop http://orcid.org/0000-0002-1908-3307
Funding for this research was provided by:
This manuscript was supported by Takeda Development Center Americas, Inc., Lexington, MA, USA
Article History
Received: 3 November 2023
Revised: 22 December 2023
Accepted: 15 January 2024
First Online: 29 January 2024
Competing interests
: EJ: Research grants and advisory roles (AbbVie, Adaptive Biotechnologies, Amgen, ASTX, Ascentage, Bristol Myers Squibb, Genentech, Jazz, Novartis, Pfizer, Takeda). JA: Honoraria, research funding, and speakers bureau (Incyte, Pfizer); honoraria and speakers bureau (Bristol Myers Squibb, Novartis). JC: Consultancy and research funding (Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Astellas, Novartis, Pfizer, Takeda, BioPath Holdings); research funding (Sun Pharma, Telios, Arog, Merus, Immunogen); membership on an entity’s board of directors or advisory committees (BioPath Holdings); consultancy (Amphivena Therapeutics, BiolineRx). DR: Steering committee (Novartis); advisory board (Incyte, Pfizer, Novartis). MD: Consultancy, membership on an entity’s board of directors or advisory committees, part of a study management committee and research funding (Blueprint Medicines Corporation, Cogent); consultancy (Fusion Pharma, Medscape, DisperSol); consultancy, membership on an entity’s board of directors or advisory committees, and research funding (Takeda); consultancy and membership on an entity’s board of directors or advisory committees (Sangamo, CTO BioPharma); consultancy and research funding (Novartis); consultancy, honoraria, and research funding (Incyte); research funding (SPARC, DisperSol, Leukemia & Lymphoma Society). EA: Advisory board member and consultancy (Incyte, Novartis, Pfizer); honoraria (Bristol Myers Squibb). CC: Honoraria (Korea Otsuka Pharmaceutical); honoraria and research funding (Bristol Myers Squibb, Novartis); travel and research funding (Pfizer). DJD: Consulting and advisory role (Amgen, Autolos, Blueprint, Forty-Seven, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, and Takeda), research funding (all to institution: Novartis, AbbVie, GlycoMimetics, Blueprint Medicines). JD: Equity ownership (Magenta Therapeutics, WUGEN); board and advisory membership (RiverVest Venture Partners); research funding (Amphivena Therapeutics, NeoImmune Tech, Macrogenics, Incyte, BiolineRx, WUGEN); speaking fees (Incyte); patents/pending patents (CART with WashU and WUGEN, VLA-4 Inhibitors with WashU and Magenta). AH: Honoraria and research funding (Novartis, Incyte); research funding (Bristol Myers Squibb, Pfizer, MSD). JHL: Consultancy and research funding (Bristol Myers Squibb, ARIAD, Pfizer, Novartis). MM: Consultancy, honoraria, travel, accommodation, expenses, and research funding (Bristol Myers Squibb, Novartis, Takeda, Pfizer); research funding (Sun Pharma/SPARC). FN: Honoraria, speakers bureau, travel, accommodations, and expenses (Novartis, Incyte Biosciences, Pfizer); consulting and advisory role (Sun Pharma, Novartis, Analysis group); research fundings (Incyte Biosciences, Novartis); board entity (Novartis, Pfizer; Incyte Biosciences). JP-I: Consulting and advisory role (AbbVie, Janssen, AstraZeneca, Novartis, TG Therapeutics, Takeda); speakers bureau (AbbVie, Janssen, AstraZeneca, Takeda); research funding (MEI, Sunesis); patents, royalties, and other intellectual property (Sellas). GR: Research funding and speakers bureau (Pfizer); speakers bureau (Bristol Myers Squibb, Incyte, Novartis). PR: Consultancy and research funding (Incyte, Pfizer); consultancy (Bristol Myers Squibb, Novartis, Takeda). NS: Research funding (Bristol Myers Squibb). MT: Grant funding and research support (Takeda, Novartis). AV: Employment (Takeda). XR: Employment (Takeda). HK: Honoraria (AbbVie, Amgen, ARIAD, Bristol Myers Squibb, Immunogen, Orsenix, Pfizer, Agios, Takeda, Actinium Pharmaceuticals); research funding (all to institution: Pfizer, Amgen, Bristol Myers Squibb, Novartis, ARIAD, Astex Pharmaceuticals, AbbVie, Agios, Cyclacel, Immunogen, Jazz Pharmaceuticals).